Is Allena Pharmaceuticals Inc (ALNA) a Stock to Watch After Gaining 18.18% This Week?

Friday, May 13, 2022 10:50 AM | InvestorsObserver Analysts

Mentioned in this article

Allena Pharmaceuticals Inc (ALNA) stock is up 18.18% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Allena Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ALNA!
See Full ALNA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ALNA Stock Today?

Allena Pharmaceuticals Inc (ALNA) stock is flat -3.53% while the S&P 500 has gained 2.3% as of 10:42 AM on Friday, May 13. ALNA is unmoved $0.00 from the previous closing price of $0.13 on volume of 26,291,547 shares. Over the past year the S&P 500 has fallen -1.04% while ALNA is down -87.96%. ALNA lost -$0.72 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Allena Pharmaceuticals Inc click here.

More About Allena Pharmaceuticals Inc

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Click Here to get the full Stock Report for Allena Pharmaceuticals Inc stock.

Share this article:

Related Articles